[Ga-68]MTP220 PET for Biodistribution and Efficacy in Pancreatic Cancer and Head and Neck Cancers

Launched by QIUBAI LI · Jun 10, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new way to help doctors detect and diagnose two types of cancer: pancreatic cancer and head and neck cancer. The researchers are testing a special imaging tool called [Ga-68]MTP220, which is a tracer used during a PET/CT scan. This tracer is not yet approved by the FDA, so the study aims to find out if it is safe and effective for spotting these cancers in the body.

People who might join this study are adults who have recently been diagnosed with pancreatic or head and neck cancer but have not yet started any treatment like surgery, chemotherapy, or radiation. If eligible, participants will receive one injection of the tracer and then have three PET/CT scans over about 2.5 hours to see how the tracer spreads through the body. A follow-up phone call will happen the next day to check for any side effects. This study does not include people with serious liver or kidney problems, those under 18, or pregnant or breastfeeding women. The goal is to improve how these cancers are found early, which could help guide better treatment decisions in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Participants older than 18 years old
• • Prior biopsy showing pancreatic or head and neck malignancy
• • Participants have been newly diagnosed and not yet received definitive therapy (including surgery, radiation therapy, or systemic therapy).
• • Able and willing to provide written informed consent before any protocol-specific procedures are undertaken
• • Participants willing and able to undergo a PET/CT
• Exclusion Criteria:
• • Participants who do not meet the above mentioned inclusion criteria
• • Participants with severe hepatic and renal dysfunction (Total bilirubin \> 3 mg/dL, Albumin \< 2.8 g/dL, INR \> 2.3 (or prolonged PT), presence of ascites or hepatic encephalopathy (Grade III-IV) End-Stage Renal Disease (ESRD) or eGFR \< 30 mL/min/1.73m², Serum creatinine \> 4 mg/dL or rapidly rising, Need for dialysis (hemodialysis or peritoneal dialysis), uremic symptoms)
• • Participants \< 18 years old
• • Participants who refuse to give or are unable to sign the informed consent
• • Anti-cancer treatment (chemotherapy and/or radiation therapy) within the last 2 weeks
• • Participants unable to withstand or undergo PET/CT
• • Pregnant or breast feeding women.